title: Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.
abstract: Peritoneal metastasis (PM) has traditionally been approached with therapeutic nihilism. The evolution of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) over the last two decades, however, has caused a paradigm shift in treatment for PM. This modality is rapidly gaining acceptance as standard of care for PM from various cancers. This article reviews the current literature regarding the use of CRS/HIPEC for PM from the most common intra-abdominal malignancies.
authors.affiliation: Surgical Oncology Service, Department of General Surgery, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
authors.forename: Shuja
authors.initials: S
authors.lastname: Ahmed
authors.forename: John H
authors.initials: JH
authors.lastname: Stewart
authors.forename: Perry
authors.initials: P
authors.lastname: Shen
authors.forename: Konstantinos I
authors.initials: KI
authors.lastname: Votanopoulos
authors.forename: Edward A
authors.initials: EA
authors.lastname: Levine
mesh_terms: D000008:Abdominal Neoplasms / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000628:therapy*; D016896:Treatment Outcome
keywords: colorectal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal metastasis